Literature DB >> 16245220

Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.

Galip Ersöz1, Fulya Günşar, Zeki Karasu, Sinan Akay, Yücel Batur, Ulus Salih Akarca.   

Abstract

BACKGROUND/AIMS: Despite a proposed role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis, antioxidant approaches have not been investigated sufficiently in the therapy of nonalcoholic steatohepatitis. Our aim was to determine whether vitamin E plus C therapy is effective in normalization of liver enzymes compared to ursodeoxycholic acid treatment in patients with fatty liver disease.
METHODS: This was an open-labeled, prospective, randomized study enrolling patients with histologically proven fatty liver disease who had chronically elevated alanine aminotransferase, despite a three-month reducing diet. Patients consuming alcohol (more than 20 g/day) were excluded. The patients were randomly prescribed either oral vitamin E (600 IU/day) plus vitamin C (500 mg/day) or ursodeoxycholic acid (10 mg/kg/day). Patients were randomized as two groups to receive vitamin E plus vitamin C combination (28 patients, 10 F) or ursodeoxycholic acid treatment (29 patients, 13 F).
RESULTS: There was no significant change in body mass index before and after the treatment in both groups. At the end of six months of therapy, serum aspartate aminotransferase and aminotransferase levels significantly decreased in both treatment options. Vitamin E and C combination was more efficacious on serum aminotransferase levels than ursodeoxycholic acid, but the difference was not significant. Alanine aminotransferase decreased to normal levels in 17 of 27 (63%) and in 16 of 29 patients (55%), respectively, in the two groups. Gamma-glutamyl transpeptidase decreased in patients receiving ursodeoxycholic acid, but no change was obtained in the vitamin-treated patients.
CONCLUSIONS: Vitamin E plus C combination treatment is a safe, inexpensive and effective treatment option in patients with fatty liver disease, with results comparable to those obtained with ursodeoxycholic acid. Since more effective new therapeutic options are lacking, patients with fatty liver disease should be encouraged to take vitamin E and C supplements, which are safe and affordable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16245220

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  19 in total

Review 1.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

2.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 3.  Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Melinda Frye; Michael J Pagliassotti
Journal:  Antioxid Redox Signal       Date:  2011-04-26       Impact factor: 8.401

Review 4.  Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

Authors:  Juan P Arab; Roberto Candia; Rodrigo Zapata; Cristián Muñoz; Juan P Arancibia; Jaime Poniachik; Alejandro Soza; Francisco Fuster; Javier Brahm; Edgar Sanhueza; Jorge Contreras; M Carolina Cuellar; Marco Arrese; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 6.  The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Michael J Pagliassotti
Journal:  Curr Opin Investig Drugs       Date:  2008-10

Review 7.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

Review 8.  Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

Authors:  Tim C M A Schreuder; Bart J Verwer; Carin M J van Nieuwkerk; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 9.  Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Authors:  Rosa Lombardi; Simona Onali; Douglas Thorburn; Brian R Davidson; Kurinchi Selvan Gurusamy; Emmanuel Tsochatzis
Journal:  Cochrane Database Syst Rev       Date:  2017-03-30

10.  Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.

Authors:  Kei Nakajima
Journal:  Int J Hepatol       Date:  2012-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.